Asthma Therapeutics Market to 2019 – Breakthrough Biologics to Enhance Treatment of Severe Asthma and Drive Market Growth...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 7
2 Introduction 9
2.1 Disease Introduction 9
2.2 Symptoms 9
2.3 Etiology 9
2.4 Pathophysiology 10
2.5 Diagnosis 10
2.6 Assessment of Disease Severity 11
2.7 Treatment 14
2.8 Treatment Algorithm 15
3 Marketed Products 17
3.1 Product Profiles 18
3.1.1 Advair Diskus (fluticasone and salmeterol) – GlaxoSmithKline 18
3.1.2 Symbicort (budesonide/formoterol) – AstraZeneca, Co-promotion with Astellas Pharma Inc 19
3.1.3 Singulair (montelukast) – Merck & Co 19
3.1.4 Xolair (omalizumab) – Novartis and Genentech 20
3.1.5 Foradil (formoterol) – Novartis (Co-marketed by Novartis and Schering Corporation) 20
3.1.6 Dulera/Zenhale (mometasone/formoterol) – Merck & Co 21
3.1.7 Relvar/Breo – GlaxoSmithKline/Theravance 21
4 Asthma Pipeline 23
4.1 Overview 23
4.2 Mechanisms of Action in the Pipeline 26
4.3 Clinical Trials 29
4.3.1 Failure Rate 29
4.3.2 Clinical Trial Duration 34
4.3.3 Clinical Trial Size 37
4.3.4 Comparative Clinical Trial Metrics Analysis 40
4.4 Promising Pipeline Molecules 42
4.4.1 Reslizumab – Teva Pharmaceutical ltd 42
4.4.2 Mepolizumab – GlaxoSmithKline 44
4.4.3 Lebrikizumab – Roche/Genentech 46
4.4.4 Veramyst – GlaxoSmithKline 48
4.4.5 Andolast – Rottapharm Madaus 50
4.4.6 Spiriva (Tiotropium Bromide) – Boehringer Ingelheim 51
4.5 Heat Map of Safety and Efficacy for Pipeline and Marketed Products 52
5 Market Forecast to 2019 58
5.1 Geographical Markets 58
5.1.1 Global Market 59
5.1.2 North America 62
5.1.3 Top Five Countries of Europe 65
5.1.4 Japan 69
5.2 Drivers and Barriers for the Asthma Therapeutics Market 71
5.2.1 Drivers 71
5.2.2 Barriers 72
6 Strategic Consolidations 73
6.1 Major Licensing Deals 73
6.2 Major Co-development Deals 81
7 Appendix 85
7.1 All Pipeline Drugs by Phase 85
7.1.1 Discovery 85
7.1.2 Preclinical 86
7.1.3 Phase I 89
7.1.4 Phase II 90
7.1.5 Phase III 92
7.1.6 Filed 92
7.1.7 Undisclosed 93
7.2 Market Forecast to 2019 93
7.2.1 Global 93
7.2.2 US 93
7.2.3 Canada 94
7.2.4 UK 94
7.2.5 France 94
7.2.6 Germany 95
7.2.7 Italy 95
7.2.8 Spain 95
7.2.9 Japan 96
7.3 References 96
7.3.1 References for Pipeline Heat Map 100
7.3.2 References for Marketed Heat Map 101
7.4 Market Definitions 101
7.5 Abbreviations 101
7.6 Methodology 102
7.7 Coverage 103
7.8 Secondary Research 103
7.9 Therapeutic Landscape 103
7.10 Epidemiology-Based Forecasting 104
7.10.1 Analogous Forecasting Methodology 104
7.11 Market Size by Geography 105
7.11.1 Forecasting Model for Therapeutic Areas 105
7.12 Geographical Landscape 106
7.13 Pipeline Analysis 106
7.14 Competitive Landscape 106
7.14.1 Expert Panel Validation 106
7.15 Contact Us 106
7.16 Disclaimer 106